None of these studies have shown any general survival benefit over conventional treatment methods.

Follow-up studies have shown that the survival benefit lasts for years.

Earlier studies of other cancers usually placed the survival benefit in months.

A survival benefit of 12.2 weeks was seen in the combined treatment group.

There was no significant survival benefit seen for chemotherapy patients.

Still, some doctors say the hint of a survival benefit is too strong to ignore.

The results show no added survival benefit when the treatment regimen was repeated (Figure 4).

But whether that translates into a survival benefit - and how much of one - is not known.

The survival benefit was only seen among people who received both radiation and chemotherapy.

Also, the survival benefit represented a 31% relative reduction in the risk of death.